LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) — Small Pharma Inc. DMT DMTTF (the “company” or “Small pharmacy“), a biotechnology company focused on short-acting psychedelics-assisted therapies for mental illness, announces that George Tziras, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, will be attending upcoming investor conferences this September will.
Details of the sessions are as follows:
HC Wagner 24th Annual Global Investment Conference
Format: Fireside chat (virtual)
Date: September 12-14, 2022
Time: On-Demand beginning at 7:00 a.m. ET on Monday, September 12, 2022
Conference Link: Webcast Access here
Jefferies Innovation in Mental Health Summit, New York City
Format: Fireside chat (in person)
Date: September 22, 2022
Time: 8:30 a.m. ET
Conference Link: TBA – please check back next week for an update
To schedule a one-on-one meeting with the Small Pharma management team, please contact your respective conference representative or eric@lifesciadvisors.com.
The presentations and archived webcasts will also be accessible after the conferences in the Events and Conferences section of Small Pharma’s website
About Small Pharma
Small Pharma is a biotechnology company advancing a pipeline of short-acting psychedelics with therapies to treat mental illness, with a current focus on depression. Small Pharma initiated a clinical program on N,N-dimethyltryptamine (“DMT“) supported psychotherapy in February 2021. This program includes a Phase I/IIa study of the Company’s lead candidate and the development of a pipeline of proprietary preclinical assets.
About DMT
DMT is a naturally occurring psychedelic tryptamine found in plants and in the mammalian brain. Scientific evidence suggests that DMT offers the potential for both fast-acting and long-lasting antidepressant effects. DMT is characterized by its short psychedelic experience (< 30 minutes) allowing for short treatment sessions and offers...
